Literature DB >> 12057148

Hepatocellular carcinoma.

A P Venook1.   

Abstract

Early detection of hepatocellular carcinoma (HCC) is feasible, particularly in patients known to be at risk from chronic hepatitis and chronic liver disease. The optimal surveillance strategy is unknown. HCC usually presents as an incurable disease even when detected on surveillance. Surgical resection is the treatment of choice, but the coexistence of chronic liver disease and the insidious nature of HCC make it unresectable in most patients. Orthotopic liver transplantation for selected patients or ablative techniques may offer an opportunity to render patients disease-free even if the tumor is unresectable. There are numerous therapies offered to patients with unresectable HCC, including chemotherapy, hormonal therapy, and regional intra-arterial treatments. While potentially palliative, none of these approaches has been demonstrated to prolong survival in these patients. If possible, the treatment of patients with HCC should be done on clinical trials.

Entities:  

Mesh:

Year:  2000        PMID: 12057148     DOI: 10.1007/s11864-000-0068-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  24 in total

1.  Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Authors:  W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.

Authors:  S Riestra; M Rodriguez; M Delgado; A Suárez; N González; M de la Mata; G Diaz; G Miño-Fugarolas; L Rodrigo
Journal:  J Clin Gastroenterol       Date:  1998-04       Impact factor: 3.062

3.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Authors:  E Kouroumalis; P Skordilis; K Thermos; A Vasilaki; J Moschandrea; O N Manousos
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

4.  Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

Authors:  C L Lai; J Y Lau; P C Wu; H Ngan; H T Chung; S J Mitchell; T J Corbett; A W Chow; H J Lin
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

5.  Long-term survivors after resection for primary liver cancer. Clinical analysis of 19 patients surviving more than ten years.

Authors:  X D Zhou; Z Y Tang; Y Q Yu; B H Yang; Z Y Lin; J Z Lu; Z C Ma; C L Tang
Journal:  Cancer       Date:  1989-06-01       Impact factor: 6.860

6.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

7.  A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma.

Authors:  T Kanematsu; T Furuta; K Takenaka; T Matsumata; Y Yoshida; T Nishizaki; K Hasuo; K Sugimachi
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

8.  Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma.

Authors:  F Farinati; N De Maria; A Fornasiero; M Salvagnini; S Fagiuoli; M Chiaramonte; R Naccarato
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

9.  The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma.

Authors:  R E Glasgow; J A Showstack; P P Katz; C U Corvera; R S Warren; S J Mulvihill
Journal:  Arch Surg       Date:  1999-01

10.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

View more
  5 in total

1.  A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes.

Authors:  Jean C Emond; Benjamin Samstein; John F Renz
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

2.  The EIIAPA chimeric promoter for tumor specific gene therapy of hepatoma.

Authors:  Ya-Ju Hsieh; Fu-Du Chen; Chien-Chih Ke; Hsin-Ell Wang; Chih-Jen Huang; Ming-Feng Hou; Kang-Ping Lin; Juri G Gelovani; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

3.  Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma.

Authors:  Weihua Qiu; Donald David; Bingsen Zhou; Peiguo G Chu; Bohe Zhang; Mengchao Wu; Jiacheng Xiao; Tianquan Han; Zhenggang Zhu; Tianxiang Wang; Xiyong Liu; Richard Lopez; Paul Frankel; Ambrose Jong; Yun Yen
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

4.  Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro.

Authors:  Ming Shi; Fu-Sheng Wang; Zu-Ze Wu
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

5.  GHGKHKNK octapeptide (P-5m) inhibits metastasis of HCCLM3 cell lines via regulation of MMP-2 expression in in vitro and in vivo studies.

Authors:  Xiao Han; Dong-Mei Yan; Xiang-Feng Zhao; Hiroshi Matsuura; Matsuura Hiroshi; Wei-Guang Ding; Peng Li; Shuang Jiang; Bai-Rong Du; Pei-Ge Du; Xun Zhu
Journal:  Molecules       Date:  2012-02-02       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.